Latest news

• Roche posts minor sales miss in Q4 as biosimilar pressure grows

  Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely  Perjeta (pertuzumab) for HER2-positive breast cancer,   Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy  Hemlibra (emicizumab) and

• Novartis gets EU approval for multiple sclerosis therapy Mayzent

  In recent years, drugs such as Roche’s Ocrevus have  improved the treatment options available to patients with relapsing-remitting multiple sclerosis and the primary progressive form of the disease.

• Mylan, Biocon’s Herceptin biosimilar launched in US

  Roche is also counting on its  new-generation products to help counter the offset of cut-price biosimilar competition, such as multiple sclerosis therapy Ocrevus (ocrelizumab), PD-L1 Tecentriq (atezolizumab) and

• Biogen under fire over $88,000 Vumerity annual price

  As well as facing pricing pressures and legal battles, Biogen will also be challenged by newly launched or anticipated rival therapies including Novartis’ Mayzent (siponimod) and Roche’s Ocrevus (ocelizumab) which

• Dupixent gains can’t keep Sanofi on a growth track

  despite greater competition from drugs like Roche’s Ocrevus (ocrelizumab), Novartis’ Mayzent (siponimod) and Merck KGaA’s Mavenclad (cladribine).